We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
Read MoreHide Full Article
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $72.48, moving +0.07% from the previous trading session. The stock lagged the S&P 500's daily gain of 0.62%. Meanwhile, the Dow gained 0.55%, and the Nasdaq, a tech-heavy index, lost 0.03%.
Coming into today, shares of the HIV and hepatitis C drugmaker had gained 3.37% in the past month. In that same time, the Medical sector gained 2.26%, while the S&P 500 gained 0.39%.
Wall Street will be looking for positivity from Gilead Sciences as it approaches its next earnings report date. In that report, analysts expect Gilead Sciences to post earnings of $1.45 per share. This would mark a year-over-year decline of 33.79%. Meanwhile, our latest consensus estimate is calling for revenue of $6.39 billion, down 13.89% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $8.07 per share and revenue of $26.48 billion, which would represent changes of +13.82% and +7.24%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.06% higher within the past month. Gilead Sciences is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Gilead Sciences's current valuation metrics, including its Forward P/E ratio of 8.97. Its industry sports an average Forward P/E of 23.56, so we one might conclude that Gilead Sciences is trading at a discount comparatively.
Also, we should mention that GILD has a PEG ratio of 0.75. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.68 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 159, putting it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Gilead Sciences (GILD) Gains But Lags Market: What You Should Know
Gilead Sciences (GILD - Free Report) closed the most recent trading day at $72.48, moving +0.07% from the previous trading session. The stock lagged the S&P 500's daily gain of 0.62%. Meanwhile, the Dow gained 0.55%, and the Nasdaq, a tech-heavy index, lost 0.03%.
Coming into today, shares of the HIV and hepatitis C drugmaker had gained 3.37% in the past month. In that same time, the Medical sector gained 2.26%, while the S&P 500 gained 0.39%.
Wall Street will be looking for positivity from Gilead Sciences as it approaches its next earnings report date. In that report, analysts expect Gilead Sciences to post earnings of $1.45 per share. This would mark a year-over-year decline of 33.79%. Meanwhile, our latest consensus estimate is calling for revenue of $6.39 billion, down 13.89% from the prior-year quarter.
For the full year, our Zacks Consensus Estimates are projecting earnings of $8.07 per share and revenue of $26.48 billion, which would represent changes of +13.82% and +7.24%, respectively, from the prior year.
It is also important to note the recent changes to analyst estimates for Gilead Sciences. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
The Zacks Rank system, which ranges from #1 (Strong Buy) to #5 (Strong Sell), has an impressive outside-audited track record of outperformance, with #1 stocks generating an average annual return of +25% since 1988. The Zacks Consensus EPS estimate has moved 1.06% higher within the past month. Gilead Sciences is currently sporting a Zacks Rank of #3 (Hold).
Investors should also note Gilead Sciences's current valuation metrics, including its Forward P/E ratio of 8.97. Its industry sports an average Forward P/E of 23.56, so we one might conclude that Gilead Sciences is trading at a discount comparatively.
Also, we should mention that GILD has a PEG ratio of 0.75. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical - Biomedical and Genetics was holding an average PEG ratio of 1.68 at yesterday's closing price.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 159, putting it in the bottom 38% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Make sure to utilize Zacks.com to follow all of these stock-moving metrics, and more, in the coming trading sessions.